Home › Retinitis Pigmentosa › NCT07502664

Development and Evaluation of Functional Visual Field and Navigation Endpoints in Moderate to Profound Inherited Retinal Disease (DEFINE-IRD)

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Diagnosis of bilateral retinitis pigmentosa (RP) or other retinal dystrophies impacting peripheral vision as confirmed from previous eye examination records
* Best-corrected visual acuity between 20/200 to HM in at least one eye.
* Reasonably fluent in English or Spanish

Exclusion Criteria:

* Cognitive impairment, memory loss or dementia sufficient in severity to preclude informed consent or in the opinion of the investigator would prevent satisfactory completion of some or all of the testing.
* Any circumstance that in the opinion of the investigator, would interfere with participation in, or compliance with the study protocol
* Current pregnancy as reported by patient

About the study

The Vision Research and Assessment Institute (VRAI) was established with the purpose of serving as a testing facility for efficacy endpoints for patients with Low Vision.

The mission of the VRAI is to enable the highest quality, standardized efficacy testing of patients with visual impairment.

The VRAI facilitates the development and refinement of existing endpoints specifically for testing patients with Low Vision.

Sponsor: Ray Therapeutics, Inc. · Participants: 25 · Started: Feb 19, 2026

Contact the study team

• Reem Jaber, MS, CGC · Phone: 949-264-3793

Official record on ClinicalTrials.gov — NCT07502664

Locations in the U.S.

Conditions

• Retinitis Pigmentosa
• Stargardt Disease
• Retinal Dystrophies

From ClinicalTrials.gov, data retrieved Oct 2, 2026. Each study sets its own eligibility; the study team decides who can join.